The compulsory licence for nexavar a landmark order

Economic and Political Weekly

Volumn 47, Issue 14, 2012, Pages 10-13

  Srinivasan, S ^a  

^a LOCOST   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860425403     PISSN: 00129976     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Available at http://www.ipindia.nic.in/ipoNew /compulsory-License- 12032012.pdf, last accessed on 18 March 2012. The order hereafter.
2. As an aside, in November 2009, the UK's National Institute of Clinical Excellence (NICE) refused to approve sorafenib for use within the National Health Service in England because it felt increasing survival in liver cancer by six months did not justify its high price - around £2,500-3,000 per patient per month. For the gut-wrenching questions this move produces, see http://news.bbc.co.uk/2/ hi/health/8367614.stm.
3. For issues in measurement of affordability, catastrophic spending and impoverishment, see Niëns, L M, et al, "Practical Measurement of Affordability: An Application to Medicines", Bull World Health Organ, 2012; 90: 219-27. See also the affidavit filed by KEI in the current case at http://keionline.org/sites/default/files/affjameslove-13Feb2012-as-Filed.pdf. See also "Access to Medicines, Vaccines and Technology", Chapter 3 of the High Level Expert Group Report on Universal Health Coverage for India, Planning Commission, New Delhi, November 2011. And see also for unaffordability of a range of medicines in India, Chapter 5 of Impoverishing the Poor: Pharmaceuticals and Drug Pricing in India, LOCOST/JSS, Vadodara/Bilaspur, December 2004. Also available online at: http://www.scribd.com/my-document- collections/2879052
4. Some of the medicines mentioned are courtesy the reporting on an RTI sought by Shamnad Basheer et al, reported at http://spicyipindia.blogspot.in/ 2011/04/non-working-of-patent-working-norms. html). See also Table 7 in Sudip Chaudhuri, "Multinationals and Monopolies: Pharmaceutical Industry in India after TRIPS", Economic & Political Weekly, 24 March 2012, Vol XLVII.